Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioDynamics and Holos Life Sciences will together develop non-invasive epigenetic biomarkers associated with sports-related concussions, Oxford said Monday.
Oxford BioDynamics has appointed a new Senior Vice President of Commercial Development to be based in the US. The new VP is Martin Reeves, who will take up this role in March 2017.
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.